<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044859</url>
  </required_header>
  <id_info>
    <org_study_id>ADP-0055-001</org_study_id>
    <nct_id>NCT04044859</nct_id>
  </id_info>
  <brief_title>Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in&#xD;
      subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and&#xD;
      whose urothelial, head and neck, gastric (stomach), esophagogastric junction (EGJ), non-small&#xD;
      cell lung (NSCLC), esophageal or ovarian cancer that express the MAGE-A4 protein.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2037</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>2.5 years</time_frame>
    <description>Determine if treatment with ADP-A2M4CD8 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety of ADP-A2M4CD8 through measurement of Replication -competent Retrovirus in genetically engineered T-cells</measure>
    <time_frame>15 years</time_frame>
    <description>Evaluation of RCL using PCR -based assay in peripheral blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour activity: Overall Response Rate (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity: Best overall response (BOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>BOR is per RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4CD8, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4CD8, the DOR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease (DoSD)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to have stable disease by RECIST v 1.1, the duration of period of stable disease until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>PFS is assessed from date of infusion of ADP-A2M4CD8 up until the date of disease progression per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>OS is assessed from date of infusion of ADP-A2M4CD8 up until the date of patient death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Head and Neck</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophagogastric Junction Disorder</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Autologous genetically modified ADP-A2M4CD8 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous genetically modified ADP-A2M4CD8 cells</intervention_name>
    <description>Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1</description>
    <arm_group_label>Autologous genetically modified ADP-A2M4CD8 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Key Inclusion criteria&#xD;
&#xD;
          -  Age ≥18 and ≤ 75 years&#xD;
&#xD;
          -  Subject is positive for at least 1 HLA-A*02 inclusion allele&#xD;
&#xD;
          -  Histologically or cytogenetically confirmed diagnosis of urothelial cancer, esophageal&#xD;
             , esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma&#xD;
             (NSCLC), head and neck or ovarian cancer.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1 prior to leukapheresis and&#xD;
             lymphodepletion.&#xD;
&#xD;
          -  Tumor shows MAGE-A4 expression as confirmed by central laboratory&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50% or the institutional lower limit of&#xD;
             normal range, whichever is lower Note: other protocol defined Inclusion/Exclusion&#xD;
             criteria may apply&#xD;
&#xD;
        Key exclusion criteria&#xD;
&#xD;
          -  Positive for any HLA-A*02 allele other than: one of the inclusion alleles&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to fludarabine, cyclophosphamide or other agents used in the study&#xD;
&#xD;
          -  Active autoimmune or immune mediated disease&#xD;
&#xD;
          -  Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases&#xD;
&#xD;
          -  Other prior malignancy that is not considered by the Investigator to be in complete&#xD;
             remission. Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C&#xD;
             virus, or human T cell leukemia virus&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
        Note: other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hong, MD</last_name>
    <phone>713-563-5844</phone>
    <email>dshong@madanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brown</last_name>
      <email>JBROWN67@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Donald Lawrence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University - School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Cole</last_name>
      <phone>314-273-0846</phone>
      <email>colet@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Van, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Grant</last_name>
      <email>GrantP@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>David Aggen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Savage</last_name>
      <phone>916-668-1462</phone>
      <email>shawna.savage@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey M Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Lowery</last_name>
      <phone>405-271-8777</phone>
      <email>Cynthia-Lowery@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Asch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Ryan</last_name>
      <email>Kara.Ryan@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natisha Muhammad</last_name>
      <email>Natisha.Muhammad@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle McCreary</last_name>
      <phone>615-524-4284</phone>
      <email>danielle.mccreary@sarahcannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Montana Simpson</last_name>
      <phone>615-524-4118</phone>
      <email>Montana.Simpson@SarahCannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danxia Ke</last_name>
      <phone>713-792-4384</phone>
      <email>DKe@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Keaton</last_name>
      <email>tkeaton@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>John A Charlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Mendiola</last_name>
      <phone>416-634-7940</phone>
      <email>genevieve.mendiola@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Marcus Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Avenida De Cordoba S/n</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gutiéerrez</last_name>
      <phone>+34 91 390 89 22</phone>
      <email>unidadfase1.imas12@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Jon Zugazagoitia Fraile</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pio</city>
        <state>Pamplona</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leyre Resano</last_name>
      <email>leyreresano@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Mercedes Egana</last_name>
      <email>megana@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Mariano Ponz-Sarvisé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Ibanez</city>
        <state>Valencia</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inma Blasco</last_name>
      <email>iblasco@incliva.es</email>
    </contact>
    <investigator>
      <last_name>Andres Cervantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Start Madrid-FJD, Fundación Jimѐnez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Perez</last_name>
      <phone>0034 91 550 48 00</phone>
      <phone_ext>2813</phone_ext>
      <email>sonia.perez@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Victor Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico, Clara Campal, HM CIOCC (START MADRID-CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Ordoñez</last_name>
      <phone>91 756 78 25</phone>
      <email>esther.ordonez@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Vazquez</last_name>
      <phone>+34 955013068</phone>
      <email>mariavazquezonco.huvr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>María Ángeles Oyarzabal</last_name>
      <email>oyarzabalma@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reyes Bernabe Caro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>T Cell Therapy</keyword>
  <keyword>SPEAR T Cell</keyword>
  <keyword>MAGE-A4</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Urothelial</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Gastric (stomach)</keyword>
  <keyword>Esophagogastric Junction (EGJ)</keyword>
  <keyword>Non-small Cell Lung (NSCLC)</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

